– USA, FL – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Dr. Douglas Losordo, M.D., Erin Borger, and Cathy Ross to its Board of Directors.
“We are delighted to announce the appointments of such prominent industry leaders to our board. Each is highly accomplished in their respective fields and are valuable additions as we begin life as a public company, and continue to make progress toward the goal of developing cell therapies for aging-related chronic disease and life-threatening conditions.” said CEO, Geoff Green.
These new board appointments took effect in connection with the recent initial public offering and listing on the Nasdaq.
About Dr. Douglas Losordo
Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as EVP, Head of Research and Development, and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the EVP, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse chronic disease, from August 2013 until November 2020. Dr. Losordo has extensive knowledge of clinical, regulatory, manufacturing, supply chain, and commercial factors unique to cellular therapy technologies as a result of his prior industry experience.
Dr. Losordo’s also previously served as a Professor of Medicine at NYU Langone Medical Center and Northwestern University’s Feinberg School of Medicine.
He received his MD from the University of Vermont College of Medicine, and his B.A. in Zoology from the University of Vermont.
About Erin Borger
Mr. Borger is a Managing Director in Wealth Management at UBS Financial Services Inc., where he has worked since 2008. Throughout the years Mr. Borger has also served as a member on several medical and non-medical boards and committees, such as the Alzheimer’s Association South Florida, Cystic Fibrosis Foundation, Palisades Medical Center, and the University of Miami, Miller School of Medicine, to name a few. Additionally, Mr. Borger has spent several years helping to support non-profit organizations with a focus on the medical field through various research and financial support.
Mr. Borger received his B.A. in Sociology from Wofford College, and also holds several securities licenses from the Financial Industry Regulatory Authority.
About Cathy Ross
Ms. Ross is a senior finance executive with over 30 years of experience. Since 2016, she has been a member of the Board of Directors and Chair of the Audit Committee of Fraud.Net, Inc., a privately held company that operates a real-time fraud detection and analytics platform. From 2006 to 2012, she was the CFO, President, and member of the Board of Directors of MotherNature.com, a privately held online retailer and information source for vitamins, supplements, minerals, and healthy products. In her role as CFO of MotherNature.com, she managed all aspects of accounting, budgeting, and financial reporting. Before that, she served as Managing Director, Private Equity of Oasis Capital Partners, VP, Investment Banking and Public Offerings of Commonwealth Associates, Product Development and Marketing Manager of Ocwen Financial Corporation, and a Senior Credit Analyst for Chase Manhattan Bank.
Ms. Ross earned a Bachelor of Arts Degree, Economics from Brown University in 1989.
Longeveron is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company’s lead investigational product is the LOMECEL-B cell-based therapy product, which is derived from culture-expanded medicinal signaling cells that are sourced from the bone marrow of young, healthy adult donors. Longeveron believes that by using the same cells that promote tissue repair, organ maintenance, and immune system function, it can develop safe and effective therapies for some of the most difficult disorders associated with the aging process and other medical disorders. Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome, and hypoplastic left heart syndrome. The Company’s mission is to advance Lomecel-B and other cell-based product candidates into pivotal Phase 3 trials, to achieve regulatory approvals, subsequent commercialization, and broad use by the healthcare community.
For more information: https://www.longeveron.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.